0001209191-21-039647.txt : 20210610
0001209191-21-039647.hdr.sgml : 20210610
20210610191229
ACCESSION NUMBER: 0001209191-21-039647
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210610
DATE AS OF CHANGE: 20210610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lichter Jay
CENTRAL INDEX KEY: 0001376355
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40475
FILM NUMBER: 211009505
MAIL ADDRESS:
STREET 1: C/O ARATANA THERAPEUTICS, INC.
STREET 2: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
CITY: LEAWOOD
STATE: KS
ZIP: 66211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Janux Therapeutics, Inc.
CENTRAL INDEX KEY: 0001817713
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822289112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-750-4700
MAIL ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-06-10
0
0001817713
Janux Therapeutics, Inc.
JANX
0001376355
Lichter Jay
C/O JANUX THERAPEUTICS, INC.
11099 N. TORREY PINES ROAD, SUITE 290
LA JOLLA
CA
92037
1
0
1
0
Common Stock
192150
I
See footnote
Series Seed Convertible Preferred Stock
Common Stock
1138665
I
See footnote
Series Seed 2 Convertible Preferred Stock
Common Stock
2382191
I
See footnote
Series A Convertible Preferred Stock
Common Stock
3371054
I
See footnote
Series B Convertible Preferred Stock
Common Stock
1153238
I
See footnote
Shares are held as follows: (i) 192,150 shares of Common Stock held by Avalon Ventures XI, L.P. (Avalon Ventures) (ii) 1,138,665 shares of common stock issuable upon conversion of Series Seed Convertible Preferred Stock held by Avalon Ventures, (iii) 2,382,191 shares of common stock issuable upon conversion of Series Seed 2 Convertible Preferred Stock held by Avalon Ventures, (iv) 674,211 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock held by Avalon Ventures, (v) 2,696,843 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock held by Avalon BioVentures SPV I, LP (ABV SPV) and (vi) 1,153,238 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock held by ABV SPV.
Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures and ABV SPV. Dr. Lichter disclaims beneficial ownership of all shares held by Avalon Ventures and ABV SPV except to the extent of his actual pecuniary interest therein, if any.
Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
/s/ Tighe Reardon, Attorney-in-Fact
2021-06-10
EX-24.3_991977
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Andrew Meyer, Maria Dobek and Tighe Reardon of Janux Therapeutics, Inc.
(the "Company"), signing individually, the undersigned's true and lawful
attorney-in-fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 1st day of June, 2021.
/s/ Jay Lichter, Ph.D.